Signboard at the Hong Kong Exchange (AP Images)

Two years in, Hong Kong’s biotech ex­per­i­ment has been val­i­dat­ed

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.

On April 30th, the two-year an­niver­sary passed of the Stock Ex­change of Hong Kong’s (HKEX) im­ple­men­ta­tion of its new biotech chap­ter. As we re­flect on it two years lat­er, this piv­otal de­ci­sion has aged well with time and is de­liv­er­ing on its promise in a big way. While ca­su­al ob­servers might re­call that the new biotech era in Hong Kong start­ed off with some grow­ing pains, list­ings have strength­ened over time to the ex­tent that Hong Kong is right up there with New York and is ar­guably even the stronger mar­ket for biotech list­ings in ear­ly 2020. The tim­ing couldn’t have been bet­ter. Just as cur­rent events il­lus­trate how vi­tal our in­dus­try is to the world, biotech is start­ing to bloom in Asia. This wouldn’t be pos­si­ble with­out the pub­lic mar­kets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.